Not that this is entirely relevant to this specific trial, but: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902221/ http://www.ncbi.nlm.nih.gov/pmc/articles/PM

Not that this is entirely relevant to this specific trial, but: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902221/ http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902221/ As great as this is, all this does is marginally boost the odds of general success for this treatment in humans from "minuscule" to "low." It's greatly encouraging news if you're trying to keep the funding train going (which they should!), but for us normal humans, this won't mean anything until at least phase 1, if not phase 2. But we all knew this already.